Effects of arginine vasopressin on the transcriptome of prefrontal cortex in autistic rat model

Zhou, Bo; Yan, Xuehui; Liu, Yang; Zheng, Xiaoli; Chen, Yunhua; Liu, Yibu; Ren, Yinshi; Peng, Jin-Gang; Zhang, Yi; Huang, Jiayu; Tang, Lei; Wen, Min

doi:10.1111/jcmm.17578

Cited by 5 publications

(4 citation statements)

References 77 publications

(118 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In maternal VPA-treated monogamous prairie voles, PFC expressed less V 1a receptor mRNA together with reduced sociability [280]. Additionally, VP altered VPA-induced genetic alterations in the PFC [281].…”

Section: Social Behavioral Networkmentioning

confidence: 96%

See 1 more Smart Citation

Vasopressin as Possible Treatment Option in Autism Spectrum Disorder

László,

Vörös,

Correia

et al. 2023

Biomedicines

View full text Add to dashboard Cite

Autism spectrum disorder (ASD) is rather common, presenting with prevalent early problems in social communication and accompanied by repetitive behavior. As vasopressin was implicated not only in salt-water homeostasis and stress-axis regulation, but also in social behavior, its role in the development of ASD might be suggested. In this review, we summarized a wide range of problems associated with ASD to which vasopressin might contribute, from social skills to communication, motor function problems, autonomous nervous system alterations as well as sleep disturbances, and altered sensory information processing. Beside functional connections between vasopressin and ASD, we draw attention to the anatomical background, highlighting several brain areas, including the paraventricular nucleus of the hypothalamus, medial preoptic area, lateral septum, bed nucleus of stria terminalis, amygdala, hippocampus, olfactory bulb and even the cerebellum, either producing vasopressin or containing vasopressinergic receptors (presumably V1a). Sex differences in the vasopressinergic system might underline the male prevalence of ASD. Moreover, vasopressin might contribute to the effectiveness of available off-label therapies as well as serve as a possible target for intervention. In this sense, vasopressin, but paradoxically also V1a receptor antagonist, were found to be effective in some clinical trials. We concluded that although vasopressin might be an effective candidate for ASD treatment, we might assume that only a subgroup (e.g., with stress-axis disturbances), a certain sex (most probably males) and a certain brain area (targeting by means of virus vectors) would benefit from this therapy.

show abstract

Section: Social Behavioral Networkmentioning

confidence: 96%

“…In rats, i.n. VP treatment (from PND 21 for 3 weeks) improved maternal VPA injectioninduced (E12.5) social deficit, elevated the serum VP level and corrected expression changes related to synaptic and axon dysplasia and oligodendrocyte development in the PFC [281] and amygdala [144].…”

Section: Intranasal Vasopressin Applicationmentioning

confidence: 98%

Vasopressin as Possible Treatment Option in Autism Spectrum Disorder

László,

Vörös,

Correia

et al. 2023

Biomedicines

View full text Add to dashboard Cite

show abstract

“…However, there are different patterns observed in gray matter structures and long-range association fibers [ 302 ]. In addition, downregulated expression was reported in Olig2 , Mbp , and Chd7 , while upregulated expression of Lingo1 was observed in the PFC of prenatally exposed rats [ 313 ]. In this sense, CHD7 is a chromodomain helicase DNA-binding protein that promotes OL differentiation [ 314 ], and LINGO1 is a transmembrane signaling protein that inhibits OL differentiation and myelin production [ 315 ].…”

Section: Vpa and Disruption Of Brain Developmentmentioning

confidence: 99%

“…In contrast to this gain-of-function in glutamatergic neuronal differentiation, Chd7 binds strongly to H3K27ac and Sox10 / Olig2 chromatin enhancers in OPCs to promote oligodendroglial lineage differentiation [ 314 ]. However, Chd7 expression is downregulated in the PFC of rats exposed to VPA prenatally [ 313 ]. Although these differences were reported in the postnatal brain, OPCs have been identified as early as E12 in mice, which is a common timeframe for VPA prenatal exposure.…”

Section: Vpa Mechanism Of Action During Gestationmentioning

confidence: 99%

Three Decades of Valproate: A Current Model for Studying Autism Spectrum Disorder

Zarate-Lopez,

Torres-Chávez,

Gálvez-Contreras

et al. 2024

View full text Add to dashboard Cite

Autism Spectrum Disorder (ASD) is a neurodevelopmental disorder with increased prevalence and incidence in recent decades. Its etiology remains largely unclear, but it seems to involve a strong genetic component and environmental factors that, in turn, induce epigenetic changes during embryonic and postnatal brain development. In recent decades, clinical studies have shown that inutero exposure to valproic acid (VPA), a commonly prescribed antiepileptic drug, is an environmental factor associated with an increased risk of ASD. Subsequently, prenatal VPA exposure in rodents has been established as a reliable translational model to study the pathophysiology of ASD, which has helped demonstrate neurobiological changes in rodents, non-human primates, and brain organoids from human pluripotent stem cells. This evidence supports the notion that prenatal VPA exposure is a valid and current model to replicate an idiopathic ASD-like disorder in experimental animals. This review summarizes and describes the current features reported with this animal model of autism and the main neurobiological findings and correlates that help elucidate the pathophysiology of ASD. Finally, we discuss the general framework of the VPA model in comparison to other environmental and genetic ASD models.

show abstract